INFORMAX = Die Microsoft in der Biotech-Software - 500 Beiträge pro Seite

[Spanischer_Hund]

Hy Guys! Es lohnt sich mal diese Aktie näher anzuschauen - Kursziel? Natürlich dausend!!

Hier eine kleine Zusammenfassung aus dem Yahoo-Board:


The decoding of the human gene last year has set off a BOOM in biotechnology companies hoping to create treatments based on genetic variations among individuals. Here is more information on the Genomics Sector:
http://biz.yahoo.com/st/010522/24546.html

In recent weeks Genomics plays like GENE and RSTA have exploded, up more than 100%. But there are still plenty of cheap plays in the sector, with INMX:NASDAQ ($6.40) being the best fundamental play. InforMax (Nasdaq: INMX - news) is a leading global developer of bioinformatics software for High-Throughput Research(TM). Founded in 1990, today InforMax products are used by 1,870 research organizations and more than 25,000 individual scientists to understand and extract value from the massive amounts of data being generated by the Genomic Revolution. Among the Company`s customers are 23 OF THE TOP 25 PHARMACEUTICAL COMPANIES.

INMX has a growth rate over 100%, with $6.6 million of revenue in the March quarter. Despite the recent run, INMX is still trading at a deep discount to other Genomics Software plays. INMX has a Price/Sales ratio of 4 compared to 11 for GENE, 27 for RSTA, (which was recently aquired by Merck) and 36 for CRA.INMX has $4 per share cash and a book value of $4.28, giving a Price/Book of 1.50 compared to the industry average of 9.

Here is a recent recommendation from Alertinvestor:

After Rosetta Inpharmatics (RSTA) was taken out by Merck at a 70% premium, we did a little homework and discovered a stock in the same genetic testing field that, despite a 26% rise on Friday, is a leader in the field, is still selling near book value (almost all of it in cash), is growing revenues at 100% and is due to nearly break even next year. It has been under accumulation all month and it broke out of its base decisively on Friday. This company won`t remain independent long either, and the train has barely left the station. Get on board!

InforMax (INMX, 4.79, NAS) is a global provider of bioinformatic software solutions, enabling a full range of gene-to-genome analysis, interpretation and data mining. INMX sells proprietary software that enables the analysis and interpretation of genomic, proteomic and other biomolecular data that form the genetic blueprint of all living organisms. The company`s principal High-Throughput Research software products are the Vector NTI Suite for desktop computers and the more powerful and expensive GenoMax enterprise platform for computer networks. InforMax Inc. For example, Abgenix (ABGX) signed a GenoMax license in the first quarter. Building on its existing strengths, INMX intends to grow its business through increased software sales and add new revenue through professional services, distribution alliances and e-commerce offerings.

After 70% year-to-year revenue growth in 2000, the March quarter brought an increase in the growth rate to 105%, with $6.6M in revenues. The Q1 loss before extraordinary items was 19c per share, down from 46c in 2000. Book value now stands at about $4.50, just a bit higher than their cash balance of nearly $4.00 per share. The company said it should match analysts` forecast of a 62c loss this year; the consensus for 2002 stands at a loss of 9c a share. Alex Titomirov, Ph.D. - a distinguished Russian-trained expert in DNA transfer technology who taught at Columbia - is Chairman and CEO. He said that "InforMax will become profitable by the fourth quarter of 2002 and is very optimistic about the Company`s prospects for solidifying its leadership position in the bioinformatics software market. InforMax is best positioned in the industry to support the scientific community in drug discovery and in better understanding the causes of disease by increasing the effectiveness and reducing the time and investment it takes to identify and validate biological targets and discover effective treatments for disease."

[wachholder]

Hab mir die Aktie vor ca. 3 Wochen ins Depot gelegt.
Der Wert ist total unterbewertet. Bis Jahresende werden wir hier 2-stellige Kurse sehen.
Zur Zeit findet im Biotech-Bereich eine Konsolidierungswelle statt. Bei dem Kurs ist INMX ein klarer Übernahmekandidat. Ich bin gespannt wie es weiter geht.

[Spanischer_Hund]

@wachholder
Hi! Ich glaube nicht, daß wir für zweistellige Kurse bis Jahresende warten müssen! Bißchen blöd ist es, daß sie in D so wenig gehandelt wird!
Gruß, S_H

[Spanischer_Hund]

Verkäufer auf Island: Fehlanzeige!! -- Bin fest der Überzeugung, daß Informax gerade erst am Starten ist und bis Jahresende problemlos 15 $ sehen kann!!! Wenn das neue Genomax-System als Windows der Bioinformatik gesehen wird, ist für ordentlich Kursfantasie gesorgt! Zu beachten ist auch, daß Informax als pot. Übernahmekandidat gilt!!

Gruß S_H

[Spanischer_Hund]

@all

Es interessiert zwar im Moment noch (fast) niemand, aber hier mal der Chart - alte Höhen auch kurzfristig nicht ausgeschlossen:



Grüße, S_H

[Spanischer_Hund]

Drei riesige Blöcke after Hours:

15.000 zu 7.71
20.000 zu 7.80
30.000 zu 7.69

http://quotes.nasdaq.com/quote.dll?page=afterhours&mode=fram… selected=INMX%60

[Spanischer_Hund]

Und ein kleines BUY-Rating:

Wednesday June 6, 2:01 pm Eastern Time
Press Release

SOURCE: M.H. Meyerson & Co.
M.H. Meyerson & Co., Inc. Initiates Coverage of Informax, Inc. (Nasdaq: INMX) with a Buy Rating

JERSEY CITY, N.J., June 6 /PRNewswire/ -- M.H. Meyerson & Co., Inc. (Nasdaq: MHMY - news) announced coverage has been initiated on Informax, Inc. (Nasdaq: INMX - news) with a Buy Rating. For more information contact Andrew H. Scott, Director of Research at 201-459-9440 or 800-422-4114; web site: http://www.mhmeyerson.com.

M.H. Meyerson & Co., Inc. is a member of the National Association of Securities Dealers, CRD number 540.

SOURCE: M.H. Meyerson & Co.

[Spanischer_Hund]

Und die nächste Kaufempfehlung:

NEW coverage Piper Jaffray $15 target

InforMax (INMX): INMX Releases Awaited New Proteomics And Genomics Modules For GenoMax Software; Buy; Price Target: $15, U.S. Bancorp Piper Jaffray

Quelle:
http://quickenexcite.multexinvestor.com/login.asp?docid=2077… 2Easp%3Fgo%3D%252Fdata%252Fmxcache%252F1%252F20778512%252EPDF%26mxdfn%3Dnologon% 26docid%3D20778512

[Spanischer_Hund]

Buy, Buy, Buy - die nächste:

InforMax Inc. Rated New `Buy` at Punk, Ziegel
By Donna Mcdonald

Princeton, New Jersey, June 13 (Bloomberg Data) -- InforMax Inc. (INMX US) was rated new ``buy`` in new coverage by analyst James D. Ackerman at Punk, Ziegel & Company. The 12-month target price is $15.00 per share.

Grüße, S_H

[Spanischer_Hund]

Monday June 18, 9:08 am Eastern Time
Press Release
SOURCE: Viaken Systems, Inc.

Cellular Genomics Selects Viaken Systems and InforMax as Partners For the Implementation of a GenoMax-based Bioinformatics Platform

Cellular Genomics Chooses the Viaken VDS 4500-BG System for Its GenoMax-based Bioinformatics Platform
SAN FRANCISCO, GAITHERSBURG, Md., and BETHESDA, Md., June 18 /PRNewswire/ -- (Beyond Genome Conference, Viaken booth #18, InforMax booth #8) -- Viaken Systems Inc. (Viaken(TM)), the total bioinformatics solutions provider, InforMax, Inc. (Nasdaq: INMX - news), a leading global provider of bioinformatics software solutions, and Cellular Genomics, Inc., a leading biotechnology company, today announced that they are working together to implement key elements of Cellular Genomics` bioinformatics infrastructure.

As the outsourced bioinformatics provider for Cellular Genomics, Viaken will host, manage, and support the implementation and maintenance of InforMax`s GenoMax(TM) enterprise software and related systems, using its VDS 4500-BG platform. The VDS 4500-BG platform has been designed specifically to incorporate InforMax`s flagship enterprise product, GenoMax, into a secure, state-of-the-art server architecture that can be expanded and customized based on customer requirements. GenoMax is a modular enterprise bioinformatics system that supports High-Throughput Research(TM), InforMax`s process for minimizing the time and cost of both discovering and validating valuable targets for pharmaceutical, therapeutic, and diagnostic development.

``Through this relationship, we are able to design and implement a state- of-the-art enterprise server architecture that was previously only available to the large pharmaceutical companies,`` said Dr. Andy Whitney, director of bioinformatics at Cellular Genomics. ``Using the Viaken infrastructure, the InforMax software products, and our combined scientific and technical expertise, our scientists can focus on Cellular Genomics` primary objective of functional genomics-based drug discovery.``

``Cellular Genomics will be an industry leader in the use of functional genomics to understand cellular processes and to develop new drug targets, and we are thrilled to be working with them as they build their business,`` said Andrew B. Lambert, vice president sales/marketing at Viaken. ``This agreement underlines the value proposition of the Viaken offering -- rapid deployment of a top-tier bioinformatics infrastructure, reduced cost of ownership, and superior support for the client.``

``The Viaken and InforMax partnership provides Cellular Genomics with a scalable, state-of-the-art software solution and the implementation expertise necessary to meet their R&D goals, both today, and in the future,`` said Richard Melzer, senior vice president of sales and marketing at InforMax. ``We look forward to working with Viaken to design, implement, and support a High- Throughput Research environment for Cellular Genomics.``

About Cellular Genomics

Cellular Genomics, Inc. is commercializing a uniquely integrated set of technology platforms for the identification and validation of novel drug targets, and the development of breakthrough therapeutics for major human diseases. The Company expects to set a new paradigm for genomics based drug discovery by coupling rigorous, high quality functional target validation with powerful drug discovery capabilities including proprietary cell-based high- throughput and high-content drug screens. CGI will leverage all of these capabilities to develop its own, internal drug discovery opportunities as well as to develop collaborative programs with pharmaceutical partners. More information is available at CGI`s Web site: http://www.cellulargenomics.com/.

About InforMax

InforMax (Nasdaq: INMX - news) is a leading global developer of bioinformatics software for High-Throughput Research(TM). Founded in 1990, today InforMax products are used by 1,870 research organizations and more than 25,000 individual scientists worldwide (as of March 31, 2001) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution. Among the Company`s customers are 23 of the top 25 pharmaceutical companies. The Company`s mission is to support the scientific community in drug discovery and to better understand the causes of disease. Our High- Throughput Research(TM) and comprehensive suite of bioinformatics software solutions help scientists increase their effectiveness and reduce the time and investment it takes to identify and validate biological targets and discover effective treatments for disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Its market-leading products include Vector NTI® Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax(TM) for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at the Company`s web site at http://www.informaxinc.com .

About Viaken

Viaken Systems is the total bioinformatics solutions provider, offering enabling solutions for biotechnology, pharmaceutical, and agricultural research and development. Viaken provides a range of bioinformatics solutions including hosting and managed services, strategic design and implementation services, integrated data products, collaborative research, and technical and scientific user support and training to its customers in the life sciences. The company has developed a secure optimized hosting platform called the Viaken Informatics Environment that provides its customers with access to scalable informatics platforms customizable to their specific needs, and a line of productized solutions -- the Viaken Discovery System series. For more information on Viaken, visit http://www.viaken.com .

Viaken is a trademark of Viaken Systems Inc. All other trademarks mentioned in this document are the property of their respective owners.

InforMax and the InforMax logo are registered trademarks and GenoMax and High-Throughput Research are trademarks of InforMax, Inc.

SOURCE: Viaken Systems, Inc.

[Spanischer_Hund]

Es liegt was in der Luft:

Bei einem Free-Float von nur ca. 5 Mio. Aktien wurden in den letzten Tagen seltsam viele dicke Packete gehandelt ; alleine heute gab es 3x50.000, 2x25.000 und etliche 10.000 und 5.000 er! Zu beachten auch der 121.100 Block after hours!

After Hours
Time (ET) After Hours
Price After Hours
Share Volume
16.06 $ 6.02 121100
16.00 $ 6.2 2000
16.00 $ 6.25 50000

Es kann sich jeder selbst seinen Reim daraus machen, aber da decken sich mit Sicherheit nicht nur Zocker oder zittrige Hände ein!!

Grüße S_H

[Spanischer_Hund]

Für alle die noch nicht an Bord sind - InforMax nimmt einen erneuten Anlauf auf die 10 Dollar Marke - ist nur noch eine Frage der Zeit - wer den Wert die letzten Tage beobachtet hat, konnte feststellen, daß auffällig viele Böcke >25.000 gehandelt worden sind! Außerdem befinden sich in diesem Wert fast keine Zocker, da es im Yahoo-Board gerade mal 1000 Postings gibt - meiner Meinung nach ein sehr gutes Zeichen!!!

Zur Info:
Natürlich ist InforMax mein größter Depotanteil mit mittlerweile 70 % ! Gerne würde ich noch zukaufen, aber ein bißchen Risikostreuung sollte glaub ich schon sein!

Grüße, S_H

[Spanischer_Hund]

Wednesday July 18, 11:28 am Eastern Time
Press Release
SOURCE: Cytogen Corporation
AxCell Biosciences Announces New Effort to Meet Growing Demand for Proteomics Data in Drug Discovery and Other Research
Strategy Discussed at New Genomic Technologies Exposition
PRINCETON, N.J., July 18 /PRNewswire/ -- To meet the growing demand for data on human protein interactions, AxCell Biosciences, a subsidiary of Cytogen Corporation (Nasdaq: CYTO - news), today announced that it would seek to develop a broad range of alliances for additional applications of its proprietary Genetic Diversity Library(TM), Cloning of Ligand Targets(TM), and affinity screening technologies. Collectively, these platform technologies are used to generate data for the ProChart(TM) database, AxCell`s growing database of human protein interactions. In a presentation at the New Genomic Technologies Accelerating Drug Discovery exposition in New Jersey, the Company announced that it would work to make these novel tools available to pharmaceutical manufacturers, biotechnology and medical researchers.

This new focus will work to expand the utility of AxCell`s Genetic Diversity Library, Cloning of Ligand Targets, and affinity screening technologies by generating and evaluating specific protein pathway information to aid in the development of new therapeutic compounds to treat various diseases. These technologies will also be made available for use in validating existing drug targets.

In a presentation of AxCell`s technology, Juan J. Herrero, Ph.D., director of screening at AxCell Biosciences discussed that because protein-signaling pathways play a role in many diseases, scientists are working to develop drugs that specifically target these pathways. While some interactions are considered likely to have positive clinical results, others can lead to unwanted drug side effects and toxicity. By referring to a chart of the body`s protein interactions, researchers may be able to better identify drugs that target specific pathways related to disease with the added benefit of avoiding those pathways associated with unwanted side effects.

In commenting on Dr. Herrero`s presentation, Dr. John D. Rodwell, president and chief technical officer of AxCell Biosciences, said, ``AxCell is building one of the most complete and systematic maps of protein interactions involved in human cell signaling. This data set -- known commercially as the ProChart database -- includes the first and only complete map of the known WW protein domains, which are believed to have an impact on health problems including hypertension, muscular dystrophy and immunodeficiency. AxCell is continuing to chart increasingly greater portions of the proteome and plans to add new results to ProChart on a regular basis. We expect that protein interaction data will be widely used by the global life science industry for the development of new drugs and other life science products.``

The ProChart database, marketed exclusively by InforMax, Inc. (Nasdaq: INMX - news), was introduced to the pharmaceutical and biotechnology industries in March 2001 and made commercially available in June 2001 as part of the latest version of InforMax`s GenoMax(TM) enterprise bioinformatics platform. Currently, the ProChart database contains a complete map of the known WW protein domains. By year-end, it is anticipated that the database will contain protein pathway information from several other domain families, such as PDZ and SH3. ProChart will be provided to pharmaceutical and biotechnology company subscribers on a corporate-wide basis, across all therapeutic programs and several phases of drug discovery and development from target identification and validation to lead compound prioritization. Subscription rates will correspond with the amount of data available.

``AxCell expects to map all of the protein domain families involved in signal transduction, ultimately representing millions of data points of protein pathway information. We have only begun to understand the critical role that this data will play in drug discovery in the years ahead,`` Dr. Rodwell added.

AxCell Biosciences also intends to develop versions of this information, such as protein arrays and novel protein drug targets, for other markets represented by the biotechnology industry, diagnostic companies, academic and government researchers, and physicians. Cytogen Corporation, AxCell`s parent company, will also use this technology to research and develop novel drug targets independently or via collaborative ventures -- with an initial focus on product development in prostate cancer treatment.

About AxCell Biosciences

AxCell Biosciences, a subsidiary of Cytogen Corporation, is a leader in the effort to chart protein-signaling pathways in the human proteome as a means of discovering new drug targets. In conjunction with InforMax, AxCell is developing a proprietary protein pathway database, ProChart, as a discovery and development tool for subscribers in the pharmaceutical, biotechnology and agricultural industries. AxCell is also seeking to develop alliances for the development of custom protein pathway information utilizing its proprietary Genetic Diversity Library(TM), Cloning of Ligand Targets(TM), and affinity screening technologies. For additional information on AxCell Biosciences, visit www.axcellbio.com.

About Cytogen Corporation

Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology, and a leadership position in proteomics research designed to accelerate drug discovery and development. In oncology, FDA-approved products include ProstaScint® (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) (a uniquely designed next-generation radioactive seed implant for the treatment of localized prostate cancer), Quadramet® (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer), and OncoScint CR/OV® (a monoclonal antibody-based imaging agent for colorectal and ovarian cancer). Cytogen is evolving a pipeline of oncology product candidates by exploiting its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. In addition, Cytogen plans to use AxCell`s proteomics technology to research and develop novel drug targets independently or via collaborative ventures. For more information, visit www.cytogen.com.

[Spanischer_Hund]

Tuesday July 31, 7:05 am Eastern Time
Press Release
InforMax Announces GenoMax License Agreement With Windber Research Institute
BETHESDA, Md.--(BUSINESS WIRE)--July 31, 2001--InforMax, Inc. (Nasdaq:INMX - news), a leading global provider of bioinformatics software solutions, today announced that in the second quarter ending June 30, 2001 it signed a license agreement with the Windber Research Institute (Windber, PA) for the GenoMax(TM) enterprise software system.

This agreement includes software license, system support, and professional services.

Rapidly becoming an industry standard, GenoMax is an enterprise bioinformatics system that supports High-Throughput Research(TM) (HTR), InforMax`s process for minimizing the time and cost of both discovering and validating valuable targets for pharmaceutical, therapeutic, and diagnostic development.

GenoMax is a modular family of analysis programs designed to work with one or more types of genomic and proteomic data including sequence information, gene expression data, protein structure, and protein-protein interactions. The GenoMax enterprise platform is used by more than 30 biopharmaceutical companies worldwide to leverage InforMax`s data mining and analysis capabilities.

``Managing and mining experimental data is critical to an improved understanding of disease processes. InforMax is pleased to have been selected by the Windber Research Institute as the solution provider to enable their discovery research efforts in the area of breast cancer,`` said Alex Titomirov, president and CEO of InforMax. Windber Research Institute is an offsite research laboratory for the Clinical Breast Care Project (CBCP) of the Walter Reed Army Medical Center, Washington, DC. ``We look forward to working with Windber to implement our software and provide the professional services to ensure their success.``

The Windber Research Institute (WRI) is currently one of the only fully integrated research facilities designed from the onset to be a national tissue repository linked to a functional genomics and proteomics laboratory and equipped for high throughput parallel characterization of tissue specimens to generate biologically relevant information at the DNA, RNA and protein levels.

Mr. Nick Jacobs, President/CEO of Windber Medical Center and Windber Research Institute, said he is happy to be associated with InforMax, an industry leader in bioinformatics. ``We believe that this association will be the beginning of mutually beneficial collaborations between Informax and the Windber Research Institute.`` LTC Craig Shriver MD, FACS, Chief of General Surgery and CBCP Program Director, Walter Reed Army Medical Center, believes that GenoMax will provide the genome analysis and data mining solutions needed by the CBCP for better understanding of the genetic basis for breast cancer.

About Windber Research Institute

The Windber Research Institute (WRI) is a newly established state of the art biomedical research organization in scenic western Pennsylvania. WRI, which is funded through the Henry M. Jackson Foundation, Rockville, MD, was established to conduct functional genomics and proteomics research for the comprehensive Clinical Breast Care Project (CBCP) of Walter Reed Army Medical Center (WRAMC), Washington DC and the Joyce Murtha Breast Care Center (JMBCC), Windber, PA.

WRI is using a variety of biological, bioimaging, high-density cDNA and protein profiling, Laser capture micro dissection and computational tools to carry out cutting-edge research focused on identifying disease-related molecular mechanisms associated with breast disorders, said Dr Richard I. Somiari, the Scientific Director.

WRI`s close affiliation with Walter Reed Army Medical Center, Washington DC, Uniformed Services University of the Health Sciences, Bethesda, MD, Windber Medical Center, Windber, the Conemaugh Health System, and all partners in the tissue banking initiative, means that clinically relevant information associated with each specimen is obtained and directly linked with the laboratory data in a central database.

About InforMax

InforMax (Nasdaq:INMX - news) is a leading global developer of bioinformatics software for High-Throughput Research(TM). Founded in 1990, today InforMax products are used by 1,870 research organizations and more than 25,000 individual scientists worldwide (as of March 31, 2001) to understand and extract value from the massive amounts of data being generated by the Genomic Revolution.

Among the Company`s customers are 23 of the top 25 pharmaceutical companies. The Company`s mission is to support the scientific community in drug discovery and to better understand the causes of disease. Our High-Throughput Research(TM) and comprehensive suite of bioinformatics software solutions help scientists increase the effectiveness and reduce the time and investment it takes to identify and validate biological targets and discover effective treatments for disease.

InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining. Its market-leading products include Vector NTI® Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax (TM) for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at the Company`s Web site at http://www.informaxinc.com.

Statements in this press release that are not strictly historical are ``forward-looking`` statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements.

Factors that could cause or contribute to differences include, but are not limited to, risks associated with InforMax`s technologies and the need to keep pace with rapid technological change, the Company`s dependence for future revenues on its ability to increase sales of its enterprise platform and successfully establish the GenoMax brand, the Company`s dependence on developing and maintaining strategic alliances, development and availability of competitive products or technologies, dependence on patents and the ability to defend the Company`s intellectual property rights.

These factors and others are more fully described in the Company`s annual report on Form 10-K, as filed with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s current outlook only as of the date given.

InforMax, the InforMax logo, Vector NTI, AlignX, BioPlot, and ContigExpress are registered trademarks and GenoMax and High-Throughput Research are trademarks of InforMax, Inc. All other products or company names are used for identification purposes only, and may be the trademarks of their respective owners.

[Spanischer_Hund]

In einer 1/2 Stunde kommen neue Zahlen - werde sie natürlich hier reinstellen....

Bis denne und Grüße

S_H

[Spanischer_Hund]

Hier das angekündigte Ergebniss:

BETHESDA, Md.--(BUSINESS WIRE)--August 1, 2001--InforMax, Inc. announced today that for the second quarter ended June 30, 2001, it had revenues of $ 7.6 million, representing an increase of 129% over the $3.3 million achieved for the same period last year, and total bookings of $ 8.4 million, representing an increase of 72% over the same period last year.

The revenue performance is stronger than the Company`s previous guidance of $7.0 million for the second quarter. ``Bookings`` represents the total face amount of contracted sales of Company products and services in the period.

The Company also reported a net loss per share for the second quarter, excluding certain non-cash charges related to stock based compensation, of $(0.16), compared to a net loss per share of $(0.51) for the same period last year. This net loss per share is better than the Company`s previous guidance of $(0.18).

Including these non-cash charges, the Company had a second quarter net loss per share of $(0.17) compared to a net loss per share of $(0.59) for the second quarter of 2000.

For the six months ended June 30, 2001, the Company had revenues of $14.2 million, representing an increase of 117% over the $6.5 million achieved for the same period last year, and total bookings of $15.5 million, representing an increase of 72% over the same period last year.

Excluding certain non-cash charges related to stock based compensation, the Company reported a net loss per share for the six months ended June 30, 2001 of $(0.35), compared to a net loss per share of $(0.97) for the same period in 2000.

Including these non-cash charges, the Company had a net loss per share of $(0.38) for the six months ended June 30, 2001 compared to a net loss per share of $(1.18) for the same period last year.

The Company`s net loss per share in the second quarter ended June 30, 2001, reported above, is based on weighted average common shares outstanding of 22,474,514. This amount has increased by approximately two million shares from the first quarter of 2001.

Excluding the impact of this increase in weighted average common shares outstanding, the Company`s net loss per share, excluding certain non-cash charges, would have been $(0.17) for the second quarter, which is still better than the Company`s guidance of $(0.18) on a comparable basis. For the six months ended June 30, 2001, the net loss per share, excluding certain non-cash charges, would have been $(0.39).

InforMax also stated that it continues to feel comfortable that it will meet its previous guidance for revenue estimates for the fiscal year 2001 of $32 million. The Company now estimates a net loss per share for the year, excluding non-cash charges, in the range of $(0.54) to $(0.60).

This estimate is based on projected weighted average common shares outstanding for the full-year of 22.9 million. Based on the weighted average common shares previously projected for the full year 2001 of 20.7 million, the forecasted net loss per share would be $(0.60) to $(0.66). This is an improvement versus the Company`s previously forecasted range of $(0.62) to $(0.68) net loss per share.

Alex Titomirov, Ph.D., Chairman and Chief Executive Officer, emphasized that the Company continues to be optimistic about its sales pipeline, the strength of the bioinformatics software market and its expectation of achieving profitability by the fourth quarter of 2002. ``Our second quarter revenue and total bookings results represent record levels for InforMax and serve to highlight the continued strength of both GenoMax, our enterprise bioinformatics platform, and Vector NTI Suite for the desktop,`` said Titomirov. ``During the second quarter, we added four new customers for GenoMax with orders averaging $1,046,000, compared to $545,000 in the first quarter of 2001 and $377,000 in the fourth quarter of 2000. This significant increase includes the largest single transaction that InforMax has ever completed as well as the first sale of BioRS, an integration and retrieval system for handling large amounts of genomic data, which InforMax sells as part of an exclusive distribution agreement with BioMax Informatics AG. These transactions, combined with continued strong revenue growth momentum from Vector NTI, reflect our Company`s growing success in selling our broad suite of enterprise and desktop software applications.``

``Looking forward,`` said Titomirov, ``we plan to continue to build on our leadership position in the growing markets for the enterprise and desktop bioinformatics software solutions. InforMax is best positioned in the industry to become the `partner of choice` with the scientific community in both the private, academic and public sectors, as well as with other companies looking to establish a commercial foothold in the genomics and proteomics sectors. We look to become the leading supplier of the key enabling technology to identify and validate biological targets as part of the drug discovery process. We have a strong management team in place and continue to build our R&D and sales talent to lead our anticipated accelerated growth plans for the Company. Given our strong balance sheet, with a cash position of over $70 million, combined with a broad and diverse customer base, we plan to move aggressively during the balance of 2001 to execute our strategy and grow our business through releasing new products, establishing alliances with other major players in the life sciences sector and developing our professional services business line. In addition, as our better than anticipated net loss per share results in the second quarter reflect, our bottom line performance is benefiting from the organization`s strong focus on cost management and leveraging our overhead and technical infrastructure as we ramp up revenues.``

About InforMax

InforMax (Nasdaq:INMX - news) is a leading global developer of bioinformatics software for High-Throughput Research(TM). Founded in 1990, InforMax products are currently used by 1,870 research organizations and more than 25,000 individual scientists worldwide to understand and extract value from the massive amounts of data being generated by the Genomic Revolution.

Among the Company`s customers are 23 of the top 25 pharmaceutical companies. The Company`s mission is to support the scientific community in drug discovery and to better understand the causes of disease.

Our High-Throughput Research(TM) and comprehensive suite of bioinformatics software solutions help scientists increase the effectiveness and reduce the time and investment it takes to identify and validate biological targets and discover effective treatments for disease. InforMax bioinformatics software solutions enable a full range of gene-to-genome analysis, interpretation and data mining.

Its market-leading products include Vector NTI® Suite, the most widely used software suite for enhancing laboratory productivity, and GenoMax(TM) for integrated analysis of genomic and proteomic data. Additional information about InforMax can be found at the Company`s web site at http://www.informaxinc.com.

Statements in this press release that are not strictly historical are ``forward-looking`` statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements.

Factors that could cause or contribute to differences include, but are not limited to, risks associated with the Company`s operating losses and accumulated deficit and the prospect that the Company may not achieve or maintain profitability in the future, the Company`s dependence for future revenues and its ability to increase sales of its enterprise platform and successfully establish the GenoMax brand and risks associated with InforMax`s technologies and the need to keep pace with rapid technological change.

These factors and others are more fully described in the Company`s annual report on Form 10-K and the most recent 10-Q, as filed with the Securities and Exchange Commission. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company`s current outlook only as of the date given.

Notice of Conference Call and Webcast: InforMax will host a conference call and webcast to discuss the second quarter financial results for 2001 on Thursday, August 2, 2001 at 8:45 AM Eastern time. The dial-in number to access this call is 877/822-4039; the dial-in number for international callers is 706/679-7182; the access code for the live call is 1389682.

Please call five to ten minutes prior to the scheduled start time. To access the live webcast please visit us at www.informaxinc.com and click on Investor Relations. The webcast replay will be available through August 16, 2001. A replay of the conference call will be made available for the convenience of those who are unable to call in at the scheduled time, beginning shortly after the call.

The conference call replay can be accessed by dialing 800/642-1687 for domestic callers; for international callers the dial-in number is 706/645-9291. The access code for the replay is 1389682.

Quelle:
http://biz.yahoo.com/bw/010801/2681.html

Nun, wer jetzt immer noch nicht bereit ist, in Informax zu investieren, den kann ich wirklich nicht verstehen!

Grüße, S_H

[Yippi]

@Spanischer_Hund
Ein Glas klarer Kauf.Bin heute mit ein paar Stücken eingestiegen.Vielen Dank!!!!!!!!!

[Spanischer_Hund]

Enttäuschung pur......

....war wohl der bisherige Kursverlauf!

Allerdings hat sich nichts an den langfristig sehr guten Aussichten für INMX geändert!

Ein sehr gutes Argument für den jetzigen Einstieg:

Insider-Kauf durch einen Director am 07.11.01:
He Wei Wu (director) purchased 50,000 shares on 11/7/01. The price closed at 2.98 that day and had a high/low of 3.18/2.85.

Quelle: Bloomberg